NASDAQ: NCNA
Nucana PLC Stock

$1.03-0.01 (-0.96%)
Updated Feb 6, 2025
NCNA Price
$1.03
Fair Value Price
N/A
Market Cap
$4.06M
52 Week Low
$0.85
52 Week High
$19.41
P/E
-0.07x
P/B
0.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.49
Operating Cash Flow
-$28M
Beta
1.08
Next Earnings
Mar 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A

NCNA Overview

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NCNA's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NCNA
Ranked
Unranked of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important NCNA news, forecast changes, insider trades & much more!

NCNA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NCNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NCNA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NCNA is good value based on its book value relative to its share price (0.74x), compared to the US Biotechnology industry average (5.03x)
P/B vs Industry Valuation
NCNA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NCNA due diligence checks available for Premium users.

Valuation

NCNA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.07x
Industry
-152.12x
Market
31.69x

NCNA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.74x
Industry
5.03x
NCNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NCNA's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.9M
Profit Margin
0%
NCNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$25.7M
Liabilities
$20.0M
Debt to equity
3.49
NCNA's short-term assets ($21.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NCNA's short-term assets ($21.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NCNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NCNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.1M
Investing
$23.7k
Financing
$6.2M
NCNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NCNA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NCNA$4.06M-0.96%-0.07x0.74x
GLMDC$4.04M-0.56%-0.14x0.22x
TOVXF$4.12M+3.50%-0.04x0.17x
GNPXD$4.25M0.00%-0.04x2.56x
SNPXD$4.26M+2.78%2.36x0.33x

Nucana Stock FAQ

What is Nucana's quote symbol?

(NASDAQ: NCNA) Nucana trades on the NASDAQ under the ticker symbol NCNA. Nucana stock quotes can also be displayed as NASDAQ: NCNA.

If you're new to stock investing, here's how to buy Nucana stock.

What is the 52 week high and low for Nucana (NASDAQ: NCNA)?

(NASDAQ: NCNA) Nucana's 52-week high was $19.41, and its 52-week low was $0.85. It is currently -94.69% from its 52-week high and 21.18% from its 52-week low.

How much is Nucana stock worth today?

(NASDAQ: NCNA) Nucana currently has 98,630,000 outstanding shares. With Nucana stock trading at $1.03 per share, the total value of Nucana stock (market capitalization) is $4.06M.

Nucana stock was originally listed at a price of $403.75 in Sep 28, 2017. If you had invested in Nucana stock at $403.75, your return over the last 7 years would have been -99.74%, for an annualized return of -57.39% (not including any dividends or dividend reinvestments).

How much is Nucana's stock price per share?

(NASDAQ: NCNA) Nucana stock price per share is $1.03 today (as of Feb 6, 2025).

What is Nucana's Market Cap?

(NASDAQ: NCNA) Nucana's market cap is $4.06M, as of Feb 8, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Nucana's market cap is calculated by multiplying NCNA's current stock price of $1.03 by NCNA's total outstanding shares of 98,630,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.